Ethris secures €30M debt deal from EIB to push nasal antiviral into Phase 2b
What's the deal? Munich-based biotech Ethris has signed a €30 million financing agreement with the European Investment Bank (EIB) to advance its portfolio of respiratory mRNA products. The debt facility, announced September 10, 2026, is backed by the European Commission's Health Emergency Preparedness and Response Authority (DG HERA)Dealroom has a profile for this one. Try Dealroom → under its HERA Invest programme.
What's the endgame? The money will push Ethris' lead candidate, ETH47, from a Phase 2a trial into Phase 2b trials in patients with asthma and chronic obstructive pulmonary disease (COPD). It will also support ETH52 and ETH53, two programmes focused on mucosal influenza vaccines and pandemic preparedness.
ETH47 is an mRNA-based product that encodes interferon lambda (IFNλ), designed to be delivered to the respiratory tract via inhalation or nasal spray. Rather than targeting specific viral proteins, it activates the body's innate immune defences at the point of entry — a mechanism the company says could work across multiple virus families.
Why now? Viral infections are major triggers of asthma and COPD flare-ups and are not addressed by current treatments. HERA Invest, the financing arm behind the deal, exists to strengthen Europe's readiness for cross-border health threats.
Why it matters: "ETH47 is designed to activate the body's natural innate immune response rather than targeting specific viral proteins, giving it broad potential antiviral activity against a multitude of viral families," said Carsten Rudolph, chief executive officer and co-founder of Ethris.
Nicola Beer, EIB vice president, framed the deal as backing "a promising European mRNA innovation from the laboratory towards patients." The EIB is the EU's long-term lending institution, owned by its member states, with Germany holding roughly an 18.8% share.
What could go wrong? The nasal-spray approach remains subject to clinical and regulatory success, as Beer noted. ETH47 has yet to clear Phase 2b, and both influenza programmes are earlier still.
The signal: At €30 million, this ranks among the largest debt rounds in health, sitting in the 90th percentile across 5,743 comparable deals. It signals Europe's continued push to fund homegrown mRNA innovation and shore up pandemic defences through public lending rather than dilutive venture capital.
Read more: smb.oxfordeagle.com
Image credit: f097653195018
